CRHR1 Mediates the Up-Regulation of Synapsin I Induced by Nesfatin-1 Through ERK 1/2 Signaling in SH-SY5Y Cells

Cell Mol Neurobiol. 2018 Apr;38(3):627-633. doi: 10.1007/s10571-017-0509-x. Epub 2017 Jun 12.

Abstract

The anorexigenic molecule nesfatin-1 has recently been taken as a potential mood regulator, but the potential mechanisms remain unknown. Results of our previous study have demonstrated that nesfatin-1 could induce anxiety- and depression-like behaviors in rats, accompanied by the hyperactivity of the hypothalamic-pituitary-adrenal axis and the imbalanced mRNA expression of synaptic vesicle proteins. To explore the potential neurobiological mechanism underlying the effect of nesfatin-1 on the synaptic plasticity, the human neuroblastoma SH-SY5Y cells were cultured and treated with different concentrations of nesfatin-1 in the present study. The mRNA and protein expressions of corticotropin-releasing hormone (CRH) were measured via real-time fluorescent quantitative PCR and western blot, respectively. The protein expressions of extracellular signal-regulated kinase 1/2 (ERK1/2), phosphorylated-ERK1/2 (p-ERK1/2), and synapsin I were detected via western blot. The results confirmed that nesfatin-1 (10-9~10-7 mol/L) could up-regulate the expression of CRH. Moreover, nesfatin-1 (10-9~10-7 mol/L) could also increase the protein expressions of p-ERK1/2 and synapsin I, and these effects could be blocked by CP376395, a selective antagonist of CRH type 1 receptor (CRHR1). Furthermore, the increased expression of synapsin I induced by nesfatin-1 could also be reversed by PD98059, a specific inhibitor of the p-ERK. These results indicated that CRHR1 might mediate the effect of nesfatin-1 on the expressions of synapsin I via ERK1/2 signaling pathway.

Keywords: Corticotropin-releasing hormone (CRH); Extracellular signal-regulated kinases (ERK); Hypothalamic-pituitary-adrenal (HPA) axis; Nesfatin-1; Synapsin I.

MeSH terms

  • Aminopyridines / pharmacology
  • Calcium-Binding Proteins / metabolism*
  • Cell Line
  • Corticotropin-Releasing Hormone / drug effects
  • Corticotropin-Releasing Hormone / metabolism
  • DNA-Binding Proteins / metabolism*
  • Flavonoids / pharmacology
  • Humans
  • Hypothalamo-Hypophyseal System / drug effects
  • Hypothalamo-Hypophyseal System / metabolism
  • MAP Kinase Signaling System* / drug effects
  • MAP Kinase Signaling System* / physiology
  • Mitogen-Activated Protein Kinases / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • Nerve Tissue Proteins / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism
  • Nucleobindins
  • Phosphorylation
  • Pituitary-Adrenal System / drug effects
  • Pituitary-Adrenal System / metabolism
  • Receptors, Corticotropin-Releasing Hormone / drug effects
  • Receptors, Corticotropin-Releasing Hormone / metabolism*
  • Synapsins / drug effects*
  • Synapsins / metabolism
  • Up-Regulation / drug effects

Substances

  • (3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridin-4-yl)(1-ethylpropyl)amine
  • Aminopyridines
  • Calcium-Binding Proteins
  • DNA-Binding Proteins
  • Flavonoids
  • NUCB2 protein, human
  • Nerve Tissue Proteins
  • Nucb1 protein, rat
  • Nucleobindins
  • Receptors, Corticotropin-Releasing Hormone
  • Synapsins
  • CRF receptor type 1
  • Corticotropin-Releasing Hormone
  • Mitogen-Activated Protein Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one